News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MediciNova, Inc. Announces Publication of MN-221 Clinical Results in Journal of Asthma


11/13/2012 9:01:02 AM

SAN DIEGO, Nov. 12, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced the publication of positive Phase 2 clinical results in two asthma studies in the Journal of Asthma. The publication is entitled, "Evaluation of Bedoradrine Sulfate (MN-221), a Novel, Highly Selective Beta(2)-Adrenergic Receptor Agonist for the Treatment of Asthma via Intravenous Infusion" and is available online.

Read at GlobeNewswire

comments powered by Disqus
   
Asthma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES